Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 18/20 | 0.57 |
| ▸ | CNR2 | P34972 | 17/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3570810 | 0.88 | CNR1 (0.66) | CNR1CNR2 | |
| SCHEMBL3176127 | 0.86 | CNR1 (0.57) | CNR1CNR2KCNH2 | |
| SCHEMBL3169285 | 0.86 | CNR1 (0.60) | CNR1CNR2KCNH2 | |
| SCHEMBL3169325 | 0.76 | CNR1 (0.57) | CNR1CNR2KCNH2 | |
| SCHEMBL3188747 | 0.75 | CNR1 (0.51) | CNR1CNR2KCNH2 | |
| SCHEMBL3177099 | 0.75 | CNR1 (0.51) | CNR1CNR2KCNH2 | |
| SCHEMBL3573367 | 0.75 | CNR1 (0.55) | CNR1CNR2 | |
| SCHEMBL3520860 | 0.73 | CNR1 (0.66) | CNR1CNR2KCNH2 | |
| SCHEMBL2075691 | 0.73 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL3186811 | 0.71 | CNR2 (0.74) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700634-B2 | (Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor | N.V. ORGANON (NL) | 2010-04-20 | — | — | US | disclosed |
| EP-1725232-B1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | ORGANON NV (NL) | 2008-01-23 | — | — | EP | disclosed |
| US-20070142446-A1 | (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor | MERCK SHARP & DOHME B.V. (NL) | 2007-06-21 | — | — | US | disclosed |
| EP-1725232-A1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | N.V. Organon (NL) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005089754-A1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | AKZO NOBEL N.V. (NL) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142446-A1 | (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor | CNR1, CNR2, OPRL1 | CNR1 1/4885CNR2 2/4885KCNH2 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.